theory clinical_64_3
imports Main


begin

typedecl entity
typedecl event

consts
  KinaseInhibitor :: "event ⇒ bool"
  Target :: "event ⇒ entity ⇒ bool"
  Mutations :: "entity ⇒ bool"
  PI3K_AKT_pathway :: "entity ⇒ bool"
  Inhibit :: "event ⇒ entity ⇒ bool"
  Proliferation :: "entity ⇒ bool"
  Survival :: "entity ⇒ bool"
  Treatment :: "entity ⇒ bool"
  Alpelisib :: "entity ⇒ bool"
  Fulvestrant :: "entity ⇒ bool"
  ProgressionFreeSurvival :: "entity ⇒ bool"
  Patient :: "entity ⇒ bool"
  PIK3CA_mutated :: "entity ⇒ bool"
  HR_positive :: "entity ⇒ bool"
  HER2_negative :: "entity ⇒ bool"
  AdvancedBreastCancer :: "entity ⇒ bool"
  ReceivedEndocrineTherapy :: "event ⇒ entity ⇒ bool"
  Prolonged :: "event ⇒ entity ⇒ bool"
  LessSensitive :: "entity ⇒ entity ⇒ bool"
  Chemotherapy :: "entity ⇒ bool"

(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)
axiomatization where
  explanation_1: "∀e. KinaseInhibitor e ⟶ Target e Mutations ∧ Target e PI3K_AKT_pathway ∧ Inhibit e Proliferation ∧ Inhibit e Survival"

(* Explanation 2: Treatment with alpelisib–fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. *)
axiomatization where
  explanation_2: "∀x e. Patient x ∧ PIK3CA_mutated x ∧ HR_positive x ∧ HER2_negative x ∧ AdvancedBreastCancer x ∧ ReceivedEndocrineTherapy e x ⟶ Prolonged e x ∧ ProgressionFreeSurvival x"

(* Explanation 3: A patient is likely less sensitive to chemotherapy. *)
axiomatization where
  explanation_3: "∀x. Patient x ⟶ LessSensitive x Chemotherapy"


theorem hypothesis:
 assumes asm: "Patient x ∧ ReceivedEndocrineTherapy e x"
  (* Hypothesis: If a patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation. *)
 shows "∃e. BenefitFromTreatment e ∧ Target e PIK3CA_mutated"
proof -
  (* From the premise, we know that the patient has received endocrine therapy. *)
  from asm have "Patient x ∧ ReceivedEndocrineTherapy e x" <ATP>
  (* There is a logical relation Implies(B, C), Implies(treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, patient is likely less sensitive to chemotherapy) *)
  (* We can infer that the patient is likely less sensitive to chemotherapy. *)
  from explanation_2 and asm have "Patient x ∧ PIK3CA_mutated x ∧ HR_positive x ∧ HER2_negative x ∧ AdvancedBreastCancer x ∧ Prolonged e x ∧ ProgressionFreeSurvival x" for some e <ATP>
  from explanation_3 have "Patient x ⟶ LessSensitive x Chemotherapy" <ATP>
  (* Since the patient is less sensitive to chemotherapy, they may benefit from the treatment with alpelisib-fulvestrant. *)
  then have "BenefitFromTreatment e" <ATP>
  (* The treatment targets PIK3CA mutation. *)
  from explanation_1 have "KinaseInhibitor e ⟶ Target e PIK3CA_mutated" <ATP>
  then have "Target e PIK3CA_mutated" <ATP>
  then show ?thesis <ATP>
qed

end
